文献速递妇科

Onclarity人乳头瘤病毒试验:设计、方法与基线结果

The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
PubMed 文献 · Gynecol Oncol · 2018-04-19

Onclarity试验基线阶段纳入33858名≥21岁女性,评估Onclarity HPV检测在ASC-US分诊、正常细胞学辅助检测及 primary screening 中的筛查性能。总体HPV阳性率14.7%,HPV16、18、其他12型分别为2.7%、0.8%、11.2%;验证偏倚校正后≥CIN2和≥CIN3患病率分别为1.8%和0.8%,发现5例宫颈癌(均HPV阳性)。

要点

  • ASC-US患病率5.8%,总体HPV阳性率14.7%,HPV16/18/其他12型分别为2.7%/0.8%/11.2%。
  • 验证偏倚校正后≥CIN2和≥CIN3患病率分别为1.8%和0.8%。
  • 任意HPV阳性或HPV16、18、31型与≥CIN3的比值比均达统计学显著(p<0.0001)。

核心结论

  • 本报告提供试验基线阶段参与者的人口学、细胞学、HPV基因型和组织病理学信息,进一步支持针对基因型的宫颈癌及癌前病变筛查。

研究设计与样本

  • Onclarity试验基线阶段在常规门诊就诊时纳入33858名≥21岁女性。
  • 所有细胞学异常女性、≥25岁高危HPV阳性女性及随机抽取的≥25岁细胞学和HPV均阴性女性转诊阴道镜和宫颈活检。
  • 采用验证偏倚校正并计算95%置信区间。

主要发现

  • ASC-US患病率为5.8%,总体HPV患病率为14.7%,HPV16、18和其他12型分别为2.7%、0.8%和11.2%。
  • ASC-US和HPV患病率随年龄增长呈反比。
  • 验证偏倚校正后≥CIN2和≥CIN3患病率分别为1.8%和0.8%,共发现5例宫颈癌(均HPV阳性)。
  • 任意HPV阳性基因型或HPV16、18、31型与≥CIN3的比值比相比于组织学阴性均具统计学显著性(p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The baseline phase of the Onclarity trial was conducted to determine the screening performance of the Onclarity human papillomavirus (HPV) assay for detecting cervical cancer and precancer (≥CIN2) during triage of women ≥21 years with ASC-US cytology, as an adjunct test in women ≥30 years with normal cytology and for primary screening (HPV alone) in women ≥25 years. METHODS: 33,858 women ≥21 years were enrolled during routine clinic visits. All women with abnormal cytology, women ≥25 years that were high-risk HPV positive, and a random subset of women ≥25 years, negative by cytology and for HPV, were referred for colposcopy and cervical biopsy. Verification bias adjustment with 95% confidence intervals was applied. RESULTS: ASC-US prevalence was 5.8%. The overall HPV prevalence was 14.7%; for HPV 16, 18, and the 12 other HPV types it was 2.7%, 0.8%, and 11.2%, respectively. The prevalence of ASC-US and HPV was inversely proportional with age. The verification bias adjusted prevalence of ≥CIN2 and ≥CIN3 was 1.8% and 0.8%, respectively. Overall, five cases of cervical cancer were identified (all were HPV positive). The odds ratios associated with any HPV positive genotype, or with individual genotypes HPV 16, HPV 18, and HPV 31, for ≥CIN3, were statistically significant when compared to negative histology (p < 0.0001 for all). CONCLUSIONS: This report provides demographic information, cytology findings, HPV genotype information, and histopathology for participants in the baseline phase of this trial and offers further evidence to support genotype-specific screening for cervical cancer and precancer. Clinical Trial Registry URL:https://clinicaltrials.gov/ct2/show/NCT01944722.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Stoler MH, Wright TC, Parvu V, et al. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results. Gynecol Oncol. 2018. PMID: 29681462. doi:10.1016/j.ygyno.2018.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。